$1.42
0.71% today
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US19188J3005
Symbol
COCP
Sector
Industry

Cocrystal Pharma Inc Stock price

$1.42
-0.34 19.32% 1M
-0.41 22.19% 6M
-0.60 29.70% YTD
-0.05 3.40% 1Y
-5.13 78.31% 3Y
-7.34 83.79% 5Y
-502.58 99.72% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
+0.01 0.71%
ISIN
US19188J3005
Symbol
COCP
Sector
Industry

Key metrics

Market capitalization $14.35m
Enterprise Value $6.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.51
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-17.88m
Free Cash Flow (TTM) Free Cash Flow $-15.04m
Cash position $9.94m
EPS (TTM) EPS $-1.72
P/E forward negative
Short interest 0.02%
Show more

Is Cocrystal Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Cocrystal Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Cocrystal Pharma Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Cocrystal Pharma Inc forecast:

Buy
100%

Financial data from Cocrystal Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
58% 58%
-
-0.13 -0.13
-
-
- Selling and Administrative Expenses 5.09 5.09
10% 10%
-
- Research and Development Expense 13 13
17% 17%
-
-18 -18
21% 21%
-
- Depreciation and Amortization 0.13 0.13
-
-
EBIT (Operating Income) EBIT -18 -18
16% 16%
-
Net Profit -18 -18
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cocrystal Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cocrystal Pharma Inc Stock News

Neutral
GlobeNewsWire
4 days ago
BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
Neutral
GlobeNewsWire
29 days ago
BOTHELL, Wash., March 06, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
Neutral
GlobeNewsWire
3 months ago
BOTHELL, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral influenza PB2 inhibitor CDI-42344 due to unexpectedly low influenza infection among study participants who were challenged with a H3N2 viral strain. This ra...

Company Profile

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.

Head office United States
CEO Sam Lee
Employees 11
Founded 2008
Website www.cocrystalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today